Novo seeks FDA, EMA approval for once-daily sickle cell therapy etavopivat

NVO•2026-11-13

Novo Nordisk submitted applications to the FDA and EMA seeking approval for etavopivat, an investigational once-daily therapy for adolescents and adults with sickle cell disease.

Novo seeks FDA, EMA approval for once-daily sickle cell therapy etavopivat

1. Approval applications submitted

Related News

Bath & Body Works: Morgan Stanley raises target price to $22 from $20

Spartacus Metals agrees to sell Red Lake property to Great Bear Resources for CAD 250,000 plus 2% royalty

Woori Financial Group to attend Morgan Stanley Asia Pacific Summit

Braskem 3Q26 recurring EBITDA drops 63% from 2Q26 to US$382 million

Alaunos Therapeutics registers 382,090,789 shares for resale